Synergistic CAR-T Cell Therapy Systems with Integrated Technologies

The present inventive concept integrates genetically engineered T cells with Regnase-1 and/or TGFBRII disruption with distinct technologies, such as artificial intelligence, blockchain, novel biomaterials, and Internet of Things devices, to create a more powerful and personalized CAR-T cell therapy system.

Despite the advancements in CAR-T cell therapy, current approaches often face limitations in T cell persistence and growth, leading to suboptimal treatment outcomes. The original patent addressed this issue by genetically engineering T cells with Regnase-1 and/or TGFBRII disruption, but the new inventive concept takes this a step further by synergistically combining these engineered T cells with other cutting-edge technologies to create a more robust and effective system.

The new inventive concept comprises a system for CAR-T cell therapy that integrates genetically engineered T cells with Regnase-1 and/or TGFBRII disruption with artificial intelligence for real-time monitoring and optimization of T cell growth and persistence. Additionally, the system may utilize blockchain technology for secure and transparent tracking of T cell manufacturing and clinical applications. Furthermore, the system may incorporate novel biomaterials for improved T cell viability and persistence, designed to mimic the natural T cell microenvironment. The system may also integrate Internet of Things devices for real-time monitoring of T cell activity and patient response, providing personalized feedback to optimize T cell therapy. The inventive concept also encompasses a method for predicting T cell persistence and growth by integrating the engineered T cells with machine learning algorithms and genomic data analysis.

The new inventive concept's integration of genetically engineered T cells with Regnase-1 and/or TGFBRII disruption with distinct technologies, such as AI, blockchain, novel biomaterials, and IoT devices, provides a novel and non-obvious solution to the problem of T cell persistence and growth in CAR-T cell therapy. The inventive concept's synergistic combination of these technologies enables real-time monitoring, optimization, and personalization of T cell therapy, which is not achievable with the original patent's approach alone.

Alternative embodiments of the inventive concept may include integrating the engineered T cells with other technologies, such as robotics, nanotechnology, or 3D printing, to further enhance the system's capabilities. Variations of the inventive concept may also involve using different types of genetically engineered T cells or distinct AI algorithms to optimize T cell therapy.

The inventive concept has significant commercial potential in the field of CAR-T cell therapy, with potential applications in treating various types of cancer and autoimmune diseases. The target market includes pharmaceutical and biotechnology companies, research institutions, and hospitals, with potential for widespread adoption and revenue growth.